King Wealth Management Group Acquires Shares of 98,102 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

King Wealth Management Group bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 98,102 shares of the company's stock, valued at approximately $1,768,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Coronation Fund Managers Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $1,334,000. Point72 Asset Management L.P. raised its holdings in shares of Teva Pharmaceutical Industries by 38.0% during the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company's stock worth $21,437,000 after acquiring an additional 363,217 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $6,825,000. Ritholtz Wealth Management raised its holdings in shares of Teva Pharmaceutical Industries by 269.5% during the third quarter. Ritholtz Wealth Management now owns 41,643 shares of the company's stock worth $750,000 after acquiring an additional 30,374 shares in the last quarter. Finally, Diversify Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the third quarter valued at about $640,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 1.9 %

TEVA stock traded down $0.32 during trading on Friday, reaching $16.43. 7,461,816 shares of the stock were exchanged, compared to its average volume of 9,248,161. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a 50 day simple moving average of $17.84 and a 200-day simple moving average of $17.20. Teva Pharmaceutical Industries Limited has a twelve month low of $8.64 and a twelve month high of $19.31.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several recent research reports. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 23rd. Finally, UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.